1207725-70-9

Basic information

• Product Name: 4-chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine
• Synonyms: 4-chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine
• CAS NO: 1207725-70-9
• Molecular Weight: 277.513
• Mol File: 1207725-70-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine(1207725-70-9)
• EPA Substance Registry System: 4-chloro-6-(3,4-dichloro-phenyl)-5-fluoro-pyrimidine(1207725-70-9)

Safety Data

• Hazardous Substances Data: 1207725-70-9(Hazardous Substances Data)

Upstream product

• 213265-83-9 4,6-dichloro-5-fluoropyrimidine 
• 151169-75-4 3,4-dichlophenylboronic acid 

Downstream Products

• 1207725-05-0 6-(3,4-dichlorophenyl)-5-fluoropyrimidine-4-carboxylic acid 
• 1207725-27-6 6-(3,4-dichlorophenyl)-5-fluoropyrimidine-4-carboxylic acid methyl ester 

Relevant articles and documents

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

We report on the development of a series of pyrimidine carboxylic acids that are potent and selective inhibitors of kynurenine monooxygenase and competitive for kynurenine. We describe the SAR for this novel series and report on their inhibition of KMO activity in biochemical and cellular assays and their selectivity against other kynurenine pathway enzymes. We describe the optimization process that led to the identification of a program lead compound with a suitable ADME/PK profile for therapeutic development. We demonstrate that systemic inhibition of KMO in vivo with this lead compound provides pharmacodynamic evidence for modulation of kynurenine pathway metabolites both in the periphery and in the central nervous system.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.